Outcomes and ICERs compared with current practice
| Outcomes | Polypill scenario 2A | Polypill scenario 2B | Polypill scenario 2C | Separate medication scenario 3 | |||||||||||||
| Sex\age | 40–49 | 50–59 | 60–69 | 70–75 | 40–49 | 50–59 | 60–69 | 70–75 | 40–49 | 50–59 | 60–69 | 70–75 | 40–49 | 50–59 | 60–69 | 70–75 | |
| ICER (×103 €/QALY) | Men | 6.9 | 7.8 | 8.3 | 11.4 | 6.0 | 6.8 | 7.4 | 10.3 | 5.3 | 5.9 | 6.7 | 9.6 | 4.2 | 4.4 | 6.0 | 9.6 |
| Women | NA | 8.9 | 13.9 | 17.2 | NA | 8.7 | 13.7 | 16.7 | NA | 8.4 | 12.6 | 15.8 | NA | 8.7 | 11.0 | 14.8 | |
Age- and sex-specific data for the 7.5% risk numbers in table 5.
ICERs, incremental cost-effectiveness ratios; QALY, quality-adjusted life years.